Gender has to be taken into account in diagnosing adult growth hormone deficiency by the GHRH plus arginine test

What Was Tested

Researchers studied GHRH (Growth Hormone-Releasing Hormone) in this controlled clinical trial publication.

Data on the effect of gender on the interpretation of the GHRH plus arginine stimulation test (GHRH+ARG test) is controversial.

The researchers validated the GHRH+ARG stimulation test in control subjects and patients with organic or idiopathic pituitary disease and a suspicion of adult growth hormone deficiency (AGHD) using the Immulite 2000 XPi GH assay.

Who Took Part

The study group was 126 adults.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

Identification of AGHD with the GHRH+ARG test was investigated with commonly accepted BMI-related consensus cut-off limits for peak GH concentrations.

Serum samples collected during the GHRH+ARG test were analysed for GH in 2014-2015.

What Was Measured

Topics PubMed links to this paper include Age of Onset, Arginine, Diagnostic Techniques, Endocrine, Growth Hormone-Releasing Hormone, Human Growth Hormone, Hypopituitarism and Insulin-Like Growth Factor I.

The authors tagged it with the keywords Adult GHD, BMI, GHRH+ARG and Gender.

What This Means in Plain Language

This is a controlled clinical trial of GHRH (Growth Hormone-Releasing Hormone) in 126 adults.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2017 (Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society), a journal based in Scotland.

More context: the GHRH (Growth Hormone-Releasing Hormone) compound page, all human trials.